


BioInVision Awarded SBIR Grant to Develop AI-based 3D Microscopic Imaging

BioInVision has been awarded a \$2.5M NIH SBIR grant to develop AI techniques for detecting healthy and diseased tissues from preclinical microscopic images.

CLEVELAND, OH, UNITED STATES,
November 17, 2025 /

EINPresswire.com/ -- Pre-clinical imaging research company BioInVision has been awarded a \$2.5M Small Business Innovative Research (SBIR) Phase 2 grant from the National Institutes of Health (NIH).



AI-Segmentation of whole mouse tissues and organs with therapeutic cells overlaid

The Cleveland, Ohio-based company will use this two-year award to develop artificial intelligence (AI) techniques for detecting healthy and diseased tissues from preclinical microscopic images. The project is a collaboration with Dr. Susann Brady-Kalnay (co-Principal Investigator, Professor of Molecular Biology and Microbiology) and Dr. David Wald (Professor of Pathology) from Case

Western Reserve University (Cleveland, OH). Currently, there is no existing imaging technology for a combined whole organismal level screening and targeted tissue collection. To mitigate this, BioInVision will develop an AI-driven software powered by [CryoViz](#) Imaging. "This award is a testament to BioInVision's continued quest to develop technology that reduces the cost and time spent in animal research, improve efficiency of the discovery phase of developing new drugs, and accelerate the advancement to clinical trials," stated Debashish Roy, President and CEO of BioInVision. Madhu Gargasha, Vice-President of Research and Project Principal Investigator, added "Instead of

“

This award is a testament to BioInVision's continued quest to develop technology that reduces the cost and time spent in animal research and accelerate the advancement to clinical trials”

Debashish Roy

focusing on a single organ, users can image an entire organism, capturing multiple organs in 3D in high-resolution. AI-based software will enable automatic tissue-focused investigation and section collection to study the impact of disease at a cellular and molecular level”.

This Phase 2 SBIR grant was awarded by the National Institute of General Medical Sciences. The content of this press release is solely the responsibility of the author and does not necessarily represent the official views of the NIH.

About BioInVision

BioInVision is a privately held biotechnology company offering imaging instrumentation and methodologies critical to pre-clinical studies and AI-powered software for clinical applications such as [cardiac CT perfusion](#). The patented CryoViz [cryo-imaging](#) technology is sold as an instrument and service for a variety of biomedical applications including stem cells, cancer, drug discovery, etc. Its global customers include life-scientists from academic and government institutions; biotechnology and pharmaceutical companies; hospitals and reference laboratories.

BioInVision is based in Cleveland, Ohio.

DEBASHISH ROY

BioInVision

+1 216-373-1500

inquiry@bioinvision.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/867948657>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.